Thursday, October 8th, 2020

14:00–14:15  Welcome

SESSION I – Smoldering myeloma
Chair: TBA

14:15-14:20  Introduction  
14:20-14:35  Clonal evolution in smoldering myeloma  
14:35-14:50  High-risk smoldering: what is the exact definition?
14:50-15:05  Clinical trials

15:05-15:12  Selected brief oral communication

15:12-15:40  Panel discussion

15:40-15:50  Coffee Break

SESSION II – Diagnosis of multiple myeloma
Chair: TBA

15:50-15:55  Introduction  
15:55-16:10  Diagnostic criteria and initial workup  
16:10-16:25  Genetics and risk assessment
16:25-16:40  Frailty assessment at diagnosis
16:40-16:47  Selected brief oral communication
16:47-17:15  Panel discussion

17:25  Mentored Poster Walks
13:20-14:20  Possible slot for a satellite symposium

SESSION III – Frontline therapy in patients not eligible for autologous stem cell transplantation
Chair: TBA

14:25-14:30  Introduction  Session chair
14:30-14:45  Overview phase 3 trials and newly approved treatments  Xavier Leleu (Lille)
14:45-15:00  Fit vs Frail: the European point of view  Sonja Zweegman (Amsterdam)
15:00-15:15  Fit vs frail: The point of view of North America  Hira Mian (Hamilton)
15:15-15:22  Selected brief oral communication  Speaker
15:22-15:50  Panel discussion

15:50-16:00  Coffee break

SESSION IV – Frontline therapy in patients eligible for autologous stem cell transplantation
Chair: TBA

16:00-16:05  Introduction  Session chair
16:05-16:20  Overview of European trials  Philippe Moreau (Nantes)
16:20-16:35  US point of view on new trials (including explanation of why HSCT is not proposed frontline)  Paul Richardson (Boston)
16:35-16:50  Maintenance therapy  Graham Jackson (Newcastle)
16:50-16:57  Selected brief oral communication  Speaker
16:57-17:25  Panel discussion and/or controversial debates

17:30-18:30  3 Simultaneous Meet the Expert sessions

1. Assessments for MRD evaluation  TBA
2. Definition and identification of high-risk Myeloma  TBA
3. Immunoprofiling in Myeloma  TBA
**09:30-10:30**  Possible slot for a satellite symposium

**SESSION V – MRD and the microenvironment**  
*Chair: TBA*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:35-10:40</td>
<td>Introduction</td>
</tr>
<tr>
<td>10:40-10:55</td>
<td>MRD and imaging</td>
</tr>
<tr>
<td>10:55-11:10</td>
<td>MRD and immune profiling (differences in terms of response)</td>
</tr>
<tr>
<td>11:10-11:25</td>
<td>How MRD assessment will impact clinical management</td>
</tr>
<tr>
<td>11:25-11:32</td>
<td><strong>Selected brief oral communication</strong></td>
</tr>
<tr>
<td>11:32-12:00</td>
<td>Panel discussion</td>
</tr>
</tbody>
</table>

**12:00-13:40**  Lunch

**12:30-13:30**  Possible slot for a satellite symposium

**SESSION VI – Relapsed multiple myeloma**  
*Chair: TBA*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45-14:00</td>
<td>How to sequence in 1\textsuperscript{st} and 2nd relapse?</td>
</tr>
<tr>
<td>14:00-14:15</td>
<td>Beyond 2\textsuperscript{nd} relapse</td>
</tr>
<tr>
<td>14:15-14:30</td>
<td>Overview immune therapies?</td>
</tr>
<tr>
<td>14:30-14:37</td>
<td><strong>Brief Oral Communication</strong></td>
</tr>
<tr>
<td>14:37-15:05</td>
<td>Panel discussion</td>
</tr>
</tbody>
</table>

**SESSION VII – The future: recent clinical trials in relapse**  
*Chair: TBA*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:05-15:10</td>
<td>Introduction</td>
</tr>
<tr>
<td>15:10-15:25</td>
<td>Novel targeted therapies (not immune)</td>
</tr>
<tr>
<td>15:25-15:40</td>
<td>Novel immunotherapies (part 1)</td>
</tr>
<tr>
<td>15:40-15:55</td>
<td>Novel immunotherapies (part 2)</td>
</tr>
</tbody>
</table>
Draft VIRTUAL 08/07/2020

15:55-16:02  **Brief Oral Communication**

16:02-16:25  *Panel discussion and/or controversial debates*

16:25-16:35  **Coffee break**

16:35-17:35  4 Simultaneous Breakfast Meet the Expert

1. Management of MM patients Len-refractory  
   TBA
2. How are we going to select the ideal MM patient for CAR-T?  
   TBA
3. Are there new targets in Myeloma beyond CD38?  
   TBA
4. Therapeutic strategies targeting the tumor microenvironment  
   TBA

---

**Sunday, October 11th, 2020**

10:15-11:15  Possible slot for a satellite symposium

SESSION VIII – Data management issues
Chair: TBA

11:20-11:25  Introduction  
Session chair

11:25-11:40  Access to innovative drugs: pharma-academia cooperation  
Mohamad Mohty (Paris)

11:40-11:55  iStopMM-a nationwide screening for MGUS and myeloma and early treatment of smoldering myeloma  
Sigurdur Kristinsson (Reykjavik)

11:55-12:10  Bureaucracy is strangling clinical research  
Steven Le Gouill (Nantes)

12:10-12:25  EMA vs FDA approvals: differences, why?  
Kyriaki Tzogani (Amsterdam)

12:25-13:00  **Brief Oral Communication**  
Speaker

12:32-13:00  *Panel discussion*

13:00-13:55  **Lunch**

SESSION IX – Plasma cell disorders
Chair: TBA

13:55-14:00  Introduction  
Session chair

14:00-14:15  Waldenstrom’s disease  
Jorge Castillo (Boston)

14:15-14:30  POEMS  
Arnaud Jaccard (Limoges)

14:30-14:45  Monoclonal gammopathy of clinical significance  
Jean-Paul Fermand (Paris)
14:45-15:00  Amyloidosis  Giampaolo Merliniti (Pavia)
15:00-15:05  Brief Oral Communication  Speaker
15:05-15:35  Panel discussion

MEETING CLOSURE